Treatment Optimization Pillar
BLOOM-Antimicrobial Resistance: Impacts of Intrapartum Antimicrobials on the Health of Albertan Infants
Project Key Words: Intrapartum Antimicrobials, Maternal Microbiome, Infant Resistome
Principal Investigator: Laura Sycuro, PhD, MSc
Co-Investigator(s): Ian Lewis, PhD; Tarah Lynch, PhD; Eliana Castillo, MD; Marie-Claire Arrieta, PhD;
Anita Kozyrskyj, PhD
Trainees: Joshua Potyondi, MSc Candidate
Project Theme: Innovation and Commercialization
This project aims to better understand the use of intrapartum antimicrobial prophylaxis (IAP) in Alberta and its impact on the neonatal resistome.
We will also explore how intrapartum pathogens could be more reliably detected, potentially decreasing the need for IAP exposure.
Why is This Important?
Over 25% of Albertan women receive IAP or other antimicrobial therapies during labour or shortly after giving birth. These antimicrobial exposures disrupt the natural process by which the neonate is colonized by maternal microbes and increase the burden of resistance genes in the infant microbiome.
Leveraged Sources of Support
- Snyder Institute: start-up funds
- UofC VPR: IICD Big Ideas Campaign Funds
- CIHR: Early Career Investigator Award
Knowledge & Technology Exchange and Exploitation
- Technologies for understanding how resistome inheritance and propogation occurs
- Feasibility of new approaches for detecting prevalent obstetric pathogens at POC
Highly Qualified Personnel
- 1 Masters Student
- 1 Postdoctoral Fellow
- Medical and nursing students will be involved in BLOOM data capture and analysis
- ALS faculty are partnered in exploring the feasibility of new POC diagnostics